A Randomized Trial Comparing Laparoscopic Ethanol Sclerotherapy and Surgical Removal of Ovarian Endometrioma to Preserve Ovarian Reserve

What this Trial Is About

This trial investigates women with ovarian endometrioma who are choosing surgical treatment for endometriosis. It compares two approaches laparoscopic ethanol sclerotherapy of ovarian endometrioma versus standard laparoscopic surgical removal of endometrioma. The study aims to assess ovarian reserve, as well as endometrioma recurrence, symptoms, and inflammation, over a 24-month period following surgery. Participants will be randomly assigned to receive either laparoscopic ethanol sclerotherapy or routine laparoscopic surgical excision of the endometrioma. Any other endometriosis found during surgery will be treated as usual. The study measures ovarian reserve through blood tests for anti-Mullerian hormone AMH and ultrasound counts of ovarian follicles. Recurrence will be monitored by ultrasound, symptoms tracked by questionnaires, and inflammation assessed through blood samples and endometrial biopsy. Women will be followed for 24 months after surgery with regular assessments including imaging, blood tests, and symptom questionnaires. The primary outcome is ovarian reserve at 24 months. Secondary outcomes include recurrence of endometrioma, symptom changes, and inflammation levels. The study will be conducted with single blinding and aims to provide detailed monitoring of participants ovarian function and disease status over two years.

Endometrioma Sclerotherapy and Ovarian Preservation